Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma

This study has suspended participant recruitment.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Amgen
Information provided by:
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00953446
First received: August 5, 2009
Last updated: November 18, 2010
Last verified: November 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)